Inhibition of proteasome, a proteolytic complex responsible for the degradation of ubiquitinated proteins, has emerged as a powerful strategy for treatment of multiple myeloma (MM), a plasma cell malignancy. First-in-class agent, bortezomib, has demonstrated great positive therapeutic efficacy in MM, both in pre-clinical and in clinical studies. However, despite its high efficiency, a large proportion of patients do not achieve sufficient clinical response. Therefore, the development of a second-generation of proteasome inhibitors (PIs) with improved pharmacological properties was needed. Recently, several of these new agents have been introduced into clinics including carfilzomib, marizomib and ixazomib. Further, new orally administered second-generation PI oprozomib is being investigated. This review provides an overview of main mechanisms of action of PIs in MM, focusing on the ongoing development and progress of novel anti-proteasome therapeutics.

Babak Myeloma Group Department of Pathological Physiology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Clinical Hematology University Hospital Brno Brno Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc15023496

003      

CZ-PrNML

005      

20200218135023.0

007      

ta

008      

150709s2014 enk f 000 0|eng||

009      

AR

024    7_

$a 10.1111/jcmm.12279 $2 doi

035    __

$a (PubMed)24712303

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Bešše, Lenka $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic. $7 mub2014851432

245    10

$a Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma / $c L. Kubiczkova, L. Pour, L. Sedlarikova, R. Hajek, S. Sevcikova,

520    9_

$a Inhibition of proteasome, a proteolytic complex responsible for the degradation of ubiquitinated proteins, has emerged as a powerful strategy for treatment of multiple myeloma (MM), a plasma cell malignancy. First-in-class agent, bortezomib, has demonstrated great positive therapeutic efficacy in MM, both in pre-clinical and in clinical studies. However, despite its high efficiency, a large proportion of patients do not achieve sufficient clinical response. Therefore, the development of a second-generation of proteasome inhibitors (PIs) with improved pharmacological properties was needed. Recently, several of these new agents have been introduced into clinics including carfilzomib, marizomib and ixazomib. Further, new orally administered second-generation PI oprozomib is being investigated. This review provides an overview of main mechanisms of action of PIs in MM, focusing on the ongoing development and progress of novel anti-proteasome therapeutics.

650    _2

$a lidé $7 D006801

650    _2

$a mnohočetný myelom $x farmakoterapie $x enzymologie $7 D009101

650    _2

$a proteasomový endopeptidasový komplex $x chemie $7 D046988

650    _2

$a inhibitory proteasomu $x terapeutické užití $7 D061988

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

655    _2

$a přehledy $7 D016454

700    1_

$a Pour, Luděk $7 xx0102556

700    1_

$a Sedlaříková, Lenka $7 xx0214571

700    1_

$a Hájek, Roman, $d 1964- $7 nlk20000083645

700    1_

$a Ševčíková, Sabina, $d 1972- $7 mub2015859787

773    0_

$w MED00006785 $t Journal of cellular and molecular medicine $x 1582-4934 $g Roč. 18, č. 6 (2014), s. 947-961

856    41

$u https://pubmed.ncbi.nlm.nih.gov/24712303 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20150709 $b ABA008

991    __

$a 20200218135424 $b ABA008

999    __

$a ok $b bmc $g 1083833 $s 906489

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2014 $b 18 $c 6 $d 947-961 $i 1582-4934 $m Journal of cellular and molecular medicine $n J Cell Mol Med $x MED00006785

GRA    __

$a NT12130 $p MZ0

GRA    __

$a NT14575 $p MZ0

LZP    __

$a Pubmed-20150709